DrugPatentWatch Database Preview
Dacomitinib - Generic Drug Details
What are the generic drug sources for dacomitinib and what is the scope of dacomitinib patent protection?
Dacomitinib
is the generic ingredient in one branded drug marketed by Pfizer Inc and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.Dacomitinib has fifty patent family members in forty-two countries.
Two suppliers are listed for this compound.
Summary for dacomitinib
| International Patents: | 50 |
| US Patents: | 2 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 60 |
| Clinical Trials: | 21 |
| Patent Applications: | 2 |
| DailyMed Link: | dacomitinib at DailyMed |
Synonyms for dacomitinib
| (2E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-(piperidin-1-yl)but-2-enamide |
| (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide |
| (2e)-N-{4-[(3-Chloro-4-Fluorophenyl)amino]-7-Methoxyquinazolin-6-Yl}-4-(Piperidin-1-Yl)but-2-Enamide |
| (E)-N-(4-((3-chloro-4-fluorophenyl)aMino)-7-Methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enaMide |
| (E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]-4-(piperidin-1-yl)but-2-enamide |
| (E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide |
| 1006885-28-4 |
| 1110813-31-4 |
| 1110813-31-4 pound not PF 299804 pound not PF-299804 |
| 2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxy-6-quinazolinyl)-4-(1-piperidinyl)-, (2E)- |
| 2XJX250C20 |
| AB0035896 |
| ABP000126 |
| AC-25915 |
| AKOS025401818 |
| AOB87383 |
| AOB87735 |
| BC261945 |
| BCP02530 |
| BDBM112499 |
| C24H25ClFN5O2 |
| CHEBI:132268 |
| CHEBI:91466 |
| CHEMBL2110732 |
| CS-0500 |
| D06XXH |
| D09883 |
| D5450 |
| Dacomitinib (PF299804, PF-00299804) |
| Dacomitinib (PF299804, PF299) |
| Dacomitinib (USAN/INN) |
| Dacomitinib [USAN:INN] |
| Dacomitinib anhydrous |
| Dacomitinib, PF299804 |
| dacomitinibum |
| DB11963 |
| DTXSID50149493 |
| EX-A030 |
| GTPL7422 |
| HY-13272 |
| J-500784 |
| KB-76397 |
| MLS006011275 |
| MolPort-023-293-536 |
| NCGC00263185-09 |
| PF 00299804 |
| PF 00299804-03 |
| PF-00299804 |
| PF-00299804 dacomitinib |
| PF-00299804-03 |
| PF-299 |
| PF-299804 |
| PF-299804 (Dacomitinib PF-00299804) |
| pf00299804 |
| PF299 |
| PF299804 |
| PF299804|||PF299 |
| Q-4059 |
| QCR-174 |
| RL00451 |
| s2727 |
| SC-94589 |
| SMR004703025 |
| UNII-2XJX250C20 |
| US8623883, No. 2 |
| Y0338 |
| ZINC72266312 |
US Patents and Regulatory Information for dacomitinib
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer Inc | VIZIMPRO | dacomitinib | TABLET;ORAL | 211288-001 | Sep 27, 2018 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Pfizer Inc | VIZIMPRO | dacomitinib | TABLET;ORAL | 211288-003 | Sep 27, 2018 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Pfizer Inc | VIZIMPRO | dacomitinib | TABLET;ORAL | 211288-002 | Sep 27, 2018 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for dacomitinib
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Uruguay | 28885 | ➤ Sign Up |
| Croatia | P20110958 | ➤ Sign Up |
| South Korea | 20080095915 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
